Previous studies mainly focused on the abnormal expression of TNFSF13B that promoted the occurrence of multiple sclerosis (MS) and Systemic Lupus Erythematosus (SLE).[34, 35] Interestingly, people with MS or SLE are at greater risk of developing cancer than the general population.[36, 37, 38] More importantly, TNFSF13B is reported to be enriched in tumor with hyperplastic blood vessels.[14] Consistent with these studies, our data demonstrated that high TNFSF13B expression was correlated with the tumor progression, poor prognosis, and sunitinib resistance. The gene discussed is TNFSF13B; the disease is myeloid sarcoma.